Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes
Incretin-based therapy has shifted care from glucose-centric targets to cardiorenal risk reduction. GLP-1RA are guideline-endorsed for patients with T2DM and high CV/renal risk irrespective of HbA1c; dual agonists and oral small-molecule agents may broaden indications pending definitive outcome evidence.
Authors
- Luís Corral-Gudino (ORCID: https://orcid.org/0000-0003-0151-5420)
- Miriam Gabella-Martín
- Álvaro Rodrigo-Alaíz
- José Pablo Miramontes-González
- David González-Calle
- Juana Carretero-Gómez
Institutions
- Universidad de Valladolid (ES)
- Universidad de Salamanca (ES)
- Centro de Implantología Cirugía Oral y Maxilofacial (ES)
- Hospital Universitario Río Hortega (ES)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1007/s13300-025-01829-1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00